Search

Your search keyword '"Debora Santoro"' showing total 23 results

Search Constraints

Start Over You searched for: Author "Debora Santoro" Remove constraint Author: "Debora Santoro"
23 results on '"Debora Santoro"'

Search Results

1. Efficacy and safety of CHF6001, a novel inhaled PDE4 inhibitor in COPD: the PIONEER study

2. Caffeine Citrate for Apnea of Prematurity: A Prospective, Open-Label, Single-Arm Study in Chinese Neonates

Catalog

Books, media, physical & digital resources

4. A first-in-human clinical study of a new SP-B and SP-C enriched synthetic surfactant (CHF5633) in preterm babies with respiratory distress syndrome: two-year outcomes

5. A Randomized, Controlled Trial to Investigate the Efficacy of Nebulized Poractant Alfa in Premature Babies with Respiratory Distress Syndrome

6. Late Breaking Abstract - Cumulative retrospective pharmacovigilance review of inhaled levofloxacin: drug-related aneurysms, artery dissection and cardiac valve disorders

7. Reply

8. COPD sputum eosinophils: relationship to blood eosinophils and the effect of inhaled PDE4 inhibition

9. Synthetic Surfactant CHF5633 Compared with Poractant Alfa in the Treatment of Neonatal Respiratory Distress Syndrome: A Multicenter, Double-Blind, Randomized, Controlled Clinical Trial

10. Safety, tolerability, and pharmacokinetics of single and repeat ascending doses of CHF6001, a novel inhaled phosphodiesterase-4 inhibitor: two randomized trials in healthy volunteers

11. Five-country manikin study found that neonatologists preferred using the LISAcath rather than the Angiocath for less invasive surfactant administration

12. Efficacy and safety of four doses of CHF6001, a novel inhaled phosphodiesterase-4 inhibitor (PDE4i), in patients with moderate-to-severe COPD

14. A first-in-human clinical study of a new SP-B and SP-C enriched synthetic surfactant (CHF5633) in preterm babies with respiratory distress syndrome

15. Étude de recherche de dose PIONEER : efficacité et tolérance du CHF6001, un nouvel inhibiteur de PDE4 par voie inhalée

16. Long-term efficacy and safety of aerosolized tobramycin 300 mg/4 ml in cystic fibrosis

17. Pharmacokinetic and tolerability profiles of tobramycin nebuliser solution 300 mg/4 ml administered by PARI eFlow® rapid and PARI LC Plus® nebulisers in cystic fibrosis patients

18. Safety, tolerability and pharmacokinetics of CHF 6001, a novel selective inhaled PDE4 inhibitor, in healthy volunteers

19. A novel inhaled phosphodiesterase 4 inhibitor (CHF6001) reduces the allergen challenge response in asthmatic patients

20. Netilmicin/dexamethasone fixed combination in the treatment of conjunctival inflammation

21. Long-term efficacy and safety of aerosolized tobramycin 300 mg/4 ml in cystic fibrosis

22. Efficacy And Safety Of Two Inhaled Tobramycin Solutions In Patients With Cystic Fibrosis And Chronic Pseudomonas Aeruginosa Infection: Results From A Head To Head Comparison

23. A new eye gel containing sodium hyaluronate and xanthan gum for the management of post-traumatic corneal abrasions